I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45 SEK 0.78% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

Intrinsic Value

The intrinsic value of one FLERIE stock under the Base Case scenario is 5.65 SEK. Compared to the current market price of 45 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 87%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

FLERIE Intrinsic Value
5.65 SEK
Overvaluation 87%
Intrinsic Value
Price
I
Worst Case
Base Case
Best Case

Valuation Backtest
InDex Pharmaceuticals Holding AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for FLERIE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about FLERIE?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about InDex Pharmaceuticals Holding AB

Provide an overview of the primary business activities
of InDex Pharmaceuticals Holding AB.

What unique competitive advantages
does InDex Pharmaceuticals Holding AB hold over its rivals?

What risks and challenges
does InDex Pharmaceuticals Holding AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for InDex Pharmaceuticals Holding AB.

Provide P/S
for InDex Pharmaceuticals Holding AB.

Provide P/E
for InDex Pharmaceuticals Holding AB.

Provide P/OCF
for InDex Pharmaceuticals Holding AB.

Provide P/FCFE
for InDex Pharmaceuticals Holding AB.

Provide P/B
for InDex Pharmaceuticals Holding AB.

Provide EV/S
for InDex Pharmaceuticals Holding AB.

Provide EV/GP
for InDex Pharmaceuticals Holding AB.

Provide EV/EBITDA
for InDex Pharmaceuticals Holding AB.

Provide EV/EBIT
for InDex Pharmaceuticals Holding AB.

Provide EV/OCF
for InDex Pharmaceuticals Holding AB.

Provide EV/FCFF
for InDex Pharmaceuticals Holding AB.

Provide EV/IC
for InDex Pharmaceuticals Holding AB.

Show me price targets
for InDex Pharmaceuticals Holding AB made by professional analysts.

What are the Revenue projections
for InDex Pharmaceuticals Holding AB?

How accurate were the past Revenue estimates
for InDex Pharmaceuticals Holding AB?

What are the Net Income projections
for InDex Pharmaceuticals Holding AB?

How accurate were the past Net Income estimates
for InDex Pharmaceuticals Holding AB?

What are the EPS projections
for InDex Pharmaceuticals Holding AB?

How accurate were the past EPS estimates
for InDex Pharmaceuticals Holding AB?

What are the EBIT projections
for InDex Pharmaceuticals Holding AB?

How accurate were the past EBIT estimates
for InDex Pharmaceuticals Holding AB?

Compare the revenue forecasts
for InDex Pharmaceuticals Holding AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of InDex Pharmaceuticals Holding AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of InDex Pharmaceuticals Holding AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of InDex Pharmaceuticals Holding AB compared to its peers.

Compare the P/E ratios
of InDex Pharmaceuticals Holding AB against its peers.

Discuss the investment returns and shareholder value creation
comparing InDex Pharmaceuticals Holding AB with its peers.

Analyze the financial leverage
of InDex Pharmaceuticals Holding AB compared to its main competitors.

Show all profitability ratios
for InDex Pharmaceuticals Holding AB.

Provide ROE
for InDex Pharmaceuticals Holding AB.

Provide ROA
for InDex Pharmaceuticals Holding AB.

Provide ROIC
for InDex Pharmaceuticals Holding AB.

Provide ROCE
for InDex Pharmaceuticals Holding AB.

Provide Gross Margin
for InDex Pharmaceuticals Holding AB.

Provide Operating Margin
for InDex Pharmaceuticals Holding AB.

Provide Net Margin
for InDex Pharmaceuticals Holding AB.

Provide FCF Margin
for InDex Pharmaceuticals Holding AB.

Show all solvency ratios
for InDex Pharmaceuticals Holding AB.

Provide D/E Ratio
for InDex Pharmaceuticals Holding AB.

Provide D/A Ratio
for InDex Pharmaceuticals Holding AB.

Provide Interest Coverage Ratio
for InDex Pharmaceuticals Holding AB.

Provide Altman Z-Score Ratio
for InDex Pharmaceuticals Holding AB.

Provide Quick Ratio
for InDex Pharmaceuticals Holding AB.

Provide Current Ratio
for InDex Pharmaceuticals Holding AB.

Provide Cash Ratio
for InDex Pharmaceuticals Holding AB.

What is the historical Revenue growth
over the last 5 years for InDex Pharmaceuticals Holding AB?

What is the historical Net Income growth
over the last 5 years for InDex Pharmaceuticals Holding AB?

What is the current Free Cash Flow
of InDex Pharmaceuticals Holding AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for InDex Pharmaceuticals Holding AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
InDex Pharmaceuticals Holding AB

Current Assets 987.4m
Cash & Short-Term Investments 882.2m
Receivables 90.6m
Other Current Assets 14.6m
Non-Current Assets 3.4B
Long-Term Investments 100k
PP&E 1.3m
Other Non-Current Assets 3.4B
Current Liabilities 31.6m
Accounts Payable 1.1m
Accrued Liabilities 19.3m
Other Current Liabilities 11.2m
Non-Current Liabilities 3.1m
Long-Term Debt 700k
Other Non-Current Liabilities 2.4m
Efficiency

Earnings Waterfall
InDex Pharmaceuticals Holding AB

Revenue
100k SEK
Cost of Revenue
-127m SEK
Gross Profit
-126.9m SEK
Operating Expenses
-111.9m SEK
Operating Income
-238.9m SEK
Other Expenses
48.5m SEK
Net Income
-190.4m SEK

Free Cash Flow Analysis
InDex Pharmaceuticals Holding AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

FLERIE Profitability Score
Profitability Due Diligence

InDex Pharmaceuticals Holding AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

24/100
Profitability
Score

InDex Pharmaceuticals Holding AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

FLERIE Solvency Score
Solvency Due Diligence

InDex Pharmaceuticals Holding AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

InDex Pharmaceuticals Holding AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FLERIE Price Targets Summary
InDex Pharmaceuticals Holding AB

Wall Street analysts forecast FLERIE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FLERIE is 47.26 SEK with a low forecast of 27.27 SEK and a high forecast of 71.4 SEK.

Lowest
Price Target
27.27 SEK
39% Downside
Average
Price Target
47.26 SEK
5% Upside
Highest
Price Target
71.4 SEK
59% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for FLERIE?

Click here to dive deeper.

Dividends

InDex Pharmaceuticals Holding AB
does not pay dividends
Shareholder Yield

Current shareholder yield for FLERIE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

InDex Pharmaceuticals Holding AB

Country

Sweden

Industry

Pharmaceuticals

Market Cap

3.5B SEK

Dividend Yield

0%

Description

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

Contact

STOCKHOLM
Solna
Berzelius Vag 13
+46812203850
www.indexpharma.com

IPO

2016-10-11

Employees

6

Officers

See Also

Discover More
What is the Intrinsic Value of one FLERIE stock?

The intrinsic value of one FLERIE stock under the Base Case scenario is 5.65 SEK.

Is FLERIE stock undervalued or overvalued?

Compared to the current market price of 45 SEK, InDex Pharmaceuticals Holding AB is Overvalued by 87%.

Back to Top